Company news

Corvus Pharmaceuticals, Inc. news in 2026

Corvus Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition

November 4, 2026

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026

October 29, 2026

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

September 30, 2026

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

September 3, 2026

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

August 27, 2026

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

June 8, 2026

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

April 23, 2026

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

April 21, 2026

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

March 12, 2026

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

March 4, 2026

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 23, 2026

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

January 23, 2026

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

January 21, 2026

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 20, 2026

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

January 20, 2026

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

January 16, 2026

Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference

January 5, 2026

Calls in 2026

Decks in 2026